Guidelines for economic evaluation of post-marketing Chinese patent medicine
With the premise of drug safety and effectiveness,pharmacoeconomic evaluation can provide optimal solutions for diversified decision-making application scenarios from different research perspectives while maximizing the rational utilization of existing healthcare resources.Chinese patent medicine is an essential component of pharmaceutical utilization in China and a significant part of healthcare expenditure in China.However,the economic evaluation of post-marketing Chinese patent medicine is lacking.These evaluations often lack standardization,exhibit varying quality,and are unable to effectively support healthcare decisions,indicating a need for improvement in overall quality.Given this situation,this project has gathered leading experts from China and has strictly adhered to the requirements of the group standards set by the China Association of Traditional Chinese Medicine in developing Guidelines for economic evaluation of post-marketing Chinese patent medicine,aiming to provide methodological guidance for the post-market pharmacoeconomic evaluation of Chinese patent medicine,enhancing the standardization of pharmacoeconomic evaluations of Chinese patent medicine and the scientific validity of research results,and thereby elevating the overall quality of pharmacoeconomic evaluations for post-marketing Chinese patent medicine.The guidelines adhere to the framework provided by relevant laws and regulations in China and technical guidance documents.It is based on guidance from traditional Chinese medicine(TCM)theories,focusing on the unique characteristics of TCM.It covers various aspects of pharmacoeconomic evaluation,including fundamental principles,research topic selection,research question definition,study design type selection,cost identification and measurement,health outcomes,and evaluation methods.The guidelines offer methodological recommendations and decision guidance to address common issues and challenges in the pharmacoeconomic evaluation of post-marketing Chinese patent medicine.
Chinese patent medicinepost-marketing researcheconomic evaluationguidelinegroup standard
NETL
NSTL
万方数据
